Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis

Uppal, S. K.; Kearns, Donovan G; Chat, Vipawee S; Han, George; Wu, Jashin J.

doi:10.1080/09546634.2020.1775775

Cited by 21 publications

(12 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently,the safety, tolerability and therapeutic effects of Fezakinumab (ILV-094), a human monoclonal antibody that directly binds to IL-22, have been examined in atopic dermatitis patients in severalclinical studies ( 155 ). A small scale randomized,double-blind, phase 2a clinical trial involving 60 patients with moderate-to-severe atopic dermatitis has shown that Fezakinumab is well-tolerated with sustained clinical improvements after last drug dosing.…”

Section: Therapeutic Targeting Of Il-22mentioning

confidence: 99%

Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases

et al. 2021

View full text Add to dashboard Cite

Upon antigenic stimulation, naïve CD4+T cells differentiate into different subsets and secrete various cytokines to exert biological effects. Th22 cells, a newly identified CD4+T cell subset,are distinct from the Th1, Th2 and Th17 subsets. Th22 cells secrete certain cytokines such as IL-22, IL-13 and TNF-α, but not others, such as IL-17, IL-4, or interferon-γ (IFN-γ), and they express chemokine receptors CCR4, CCR6 and CCR10. Th22 cells were initially found to play a role in skin inflammatory diseases, but recent studies have demonstrated their involvement in the development of various autoimmune diseases. Here, we review research advances in the origin, characteristics and effector mechanisms of Th22 cells, with an emphasis on the role of Th22 cells and their main effector cytokine IL-22 in the pathogenesis of autoimmune diseases. The findings presented here may facilitate the development of new therapeutic strategies for targeting these diseases.

show abstract

Section: Therapeutic Targeting Of Il-22mentioning

confidence: 99%

Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It Interrupts the IgE-dependent allergic inflammatory cascade by binding to free IgE and preventing it from binding to IgE receptors [13] .Etokimab is a human monoclonal IgG1 antibody that neutralizes IL-33. Preliminary clinical studies are currently reported in AD, and asthma [14] .In addition, there are case reports or I/II clinical trials of fezakinumab, nemolizumab, tezepelumab, Secukinumab, GBR 830 and recombinant interferon-γ for AD treatment, which are expected to be used in the treatment of other atopic comorbidities in the future [15] .This meta-analysis systematically evaluated the efficacy and safety of biologics by including a randomized, placebo-controlled study of dupilumab in the treatment of children with atopic dermatitis, and provided reference for clinical treatment.…”

Section: Discussion：atopic Dermatitis (Ad) Is a Chronic Inflammatory ...mentioning

confidence: 99%

Biologics for pediatric atopic dermatitis A protocol of A systematic review and meta - analysis

Rui

Chen

2022

Preprint

View full text Add to dashboard Cite

Background: Atopic dermatitis is a common chronic pruritic inflammatory skin disease, tends to occur in children. The objective of this study is to evaluate the treatment of pediatric atopic dermatitis with Biologics,as biologics continue to emerge for atopic dermatitis (AD) Methods: The databases we will search include Embase, Cochrane Library, Web of Science,the and PubMed of RCTs from inception to 15st May 2022. The primary outcomes The proportion of patients with EASI 75 as the primary outcome,. The secondary outcomes incloud NRS,DLQI score and adverse reaction incidence.Studies will be screened by two independent authors. They will assess the risk of bias of the final included studies according to the RCTs bias risk evaluation tool in Cochrane System Review Manual 5.1.0. Meta-analysis will be performed using RevMan 5.3 software. Results: The research results will provide a reference for the clinical application of biological agents in pediatric atopic dermatitis. Conclusion: We aims to evaluate the efficacy and safety of biologics in pediatric atopic dermatitis and provide evidence-based data for clinical application Ethics and dissemination? The study does not collect raw data and personal information, does not involve jeopardizing the rights of the participants. Ethical approval was not required. The results may be reported in publications and the media PROSPERO registration number: CRD42022319052 (https://www.crd.york.ac.uk/PROSPERO/#joinuppage) Abbreviations: AD:atopic dermatitis; RCT:randomized controlled trial;.SMD:Standard Mean Difference; RR:risk ratio;CI:confidence interval;EASI:Eczema Area and Severity Index; DLQI: Dermatology Life Quality Index; NRS?Numerical Rating Scale.

show abstract

“…80 The drug-induced an increase in the proportion of peanut-tolerating patients: 73% tolerated 275 mg of peanut protein -corresponding to two peanuts -after 14 days, 57% after 45 days. The tolerance to higher doses was inferior: 47% toler- Another drug potentially useful in this area is Tezepelumab, a TSLP antagonist used for asthma and AD, 81,82 but no clinical trials on this drug in food allergy are being conducted at the moment.…”

Section: Alarmin-targeted Treatmentsmentioning

confidence: 99%

“…Another drug potentially useful in this area is Tezepelumab, a TSLP antagonist used for asthma and AD, 81,82 but no clinical trials on this drug in food allergy are being conducted at the moment.…”

Section: Monoclonal Antibodies Showing Promise In Clinical Trials For Ige‐mediated Food Allergymentioning

confidence: 99%

The use of biologics in food allergy

Fiocchi

Vickery

Wood

2021

Clin Experimental Allergy

View full text Add to dashboard Cite

Background Food allergy continues to pose problems due to its increased frequency and its increasingly high severity. In this context, alongside the traditional avoidance strategies of allergenic foods and desensitization through the cautious progression of exposure to foods in the context of oral immunotherapy (OIT), alternative strategies have made their way in the last decades. We review the possibilities of intervention in food allergy with the use of biological drugs capable of interfering with the synthesis of IgE, with their mechanisms of action, or with complex biological mechanisms that lead to the establishment of a food allergy. Methods Repeated Entrez PubMed searches using the template algorithm “Food allergy” and “biologics” or “Omalizumab” or “Dupilumab” or “milk desensitization” or “oral tolerance induction” or “oral immunotherapy” or “Etokimab” or “Tezepelumab” or “Quilizumab” or “Ligelizumab” or “Tralokinumab” or “Nemolizumab” or “Mepolizumab” or “Reslizumab” or “Benralizumab”. The authors’ clinical experience in paediatric allergy units of University hospitals was also drawn upon. Results The landscape in this context has changed dramatically over the past 10 years. We have acquired knowledge mainly on the effect of different types of anti‐IgE treatments in poliallergic patients with food allergy, and in patients treated with OIT. However, other mediators are being targeted by specific biologic treatments. Among them, the alarmins Il‐33 and TSLP, IL‐4 and IL‐13, eosinophil‐related molecules as IL‐6, IL‐8, IL‐10, IL‐12, and mostly IL‐5, and integrins involved in the pathogenesis of eosinophilic gastrointestinal diseases (EGIDs), as SIGLEC‐8. Conclusions The ever‐better knowledge of the mechanisms of food allergy allowing these developments will improve not only the perspective of patients with the most serious immediate food allergies such as anaphylaxis, but also those of patients with related diseases such as atopic dermatitis, eosinophilic esophagitis, and EGIDs. Biologics are also intended to complement OIT strategies that have developed over the years.

show abstract

Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis

Cited by 21 publications

References 70 publications

Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases

Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases

Biologics for pediatric atopic dermatitis A protocol of A systematic review and meta - analysis

The use of biologics in food allergy

Contact Info

Product

Resources

About